TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Global perinatal morbidity and mortality
Endpoint domain: Mortality/survival
Primary endpoint: Progression-free Survival at 6 Months (Leiomyosaroma Group)
Endpoint domain: Mortality/survival
Primary endpoint: Progression-free Survival at 6 Months (Carcinosarcoma Group)
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of Subjects with Overall Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Subjects with Clinical Outcome of Cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of carbohydrate in ileostomy effluent
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of change of NO serum level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of change of cGMP serum level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of change of ET1 serum level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: systolic pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: diastolic pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: mean blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Post Surgical Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Observed Plasma Analyte concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve from Time Zero to the Last Measurable Concentration (AUC [0-last])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve from Time Zero to Infinity (AUC [0-infinity])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CO2 Reserve (Delta-PETCO2-AT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Body Glucose Disposal in the Fasting State
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: AUC of Insulin Secretion Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Size of abnormal epithelium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of isolating right and left PVs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Cmax of analyte in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-∞ of metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor verification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Respiratory Morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: post operative pain accessed by the patient
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: AUC0-72 - Area under the concentration-time curve from time zero to 72 hours post dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hypocitraturia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage Change From Baseline in Urinary N-telopeptide of Type I Collagen (u-NTx) at Week 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Response rate to SAHA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Achilles tendon function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Recruited Subjects Able to Comply With the Protocol
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: mTICI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response to the vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time-Intensity Curve (TIC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Short Warwick-Edinburg Mental Well-Being Scale (WEMWBS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Short-Form Health Survey (SF-36)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: ability to identify the cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: ability to show areas within the cancer that are potentially more active
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: CD4 helper cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Presence of contaminants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distance walked during 6 minute walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: glucagon excursions measured as incremental area under the curve (iAUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Endothelial Function Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of postoperative infection at the surgical site
Endpoint domain: Adverse events/effects
Primary endpoint: SNAP-IV scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Increase functionality of involved joint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: subgingival microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VTI changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of Multiple Organ Dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Required ICU Interventions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Viability of the flap
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of children presenting with CNM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of children with birthweight above 4500 grams
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mucosal Impedance Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Gross Motor Function Measure score (GMFM-66)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Next Generation Sequencing (NGS) tests that have a clinical impact for the patient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Sleep Quality
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Levels of ALS biomarkers in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of ALS biomarkers in CSF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: eradication rate of H. pylori
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of pepsin levels ≥200 ng/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in steps (physical activity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiac output results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Circulatory parameters of retrobulbar blood vessels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Difference in PDSD-2 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy on Gastroesophageal Reflux (GER)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: number of lymph nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: number of positive lymph nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: weight of the central compartment tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of the ultrasonography (US)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of the electromyograph (EMG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of death from any causes
Endpoint domain: Mortality/survival
Primary endpoint: Number of participants who develop diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants With at Least One Dose Reduction
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of smoking abstinence after 12 months
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Efficacy (Pain)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients who intend to contact RetinaScreen
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of patients who have contacted the national screening programme
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of patients who have attended screening
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Adherence to prescribed macronutrient composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Blood plasma concentration of IL-1 beta
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Blood plasma concentration of IL-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Blood plasma concentration of TNF-alpha
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Blood plasma concentration of CRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Aneurysm Angiographic Occlusion of ≥ 90% at 6 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Any Major Stroke or Death Within 30 Days
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants With Non-Serious Adverse Events (AEs) And Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of filled questionnaires at 12-months
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: AUClast of metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cmax of Lobeglitazone Metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Freedom from fecal incontinence reintervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Criminal Justice Outcomes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Alcohol and Drug Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Worries About HIV
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Ki67 expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physiological load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ED-50 of rocuronium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ED-95 of rocuronium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive impairment in ATS addicts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Participants With a ≥2-Step Improvement on DRSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Change in gut and oral microflora composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Changes in AAQ-II scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in VQ scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in FCRI severity subscale scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Endtidal ethanol concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Conversion rate of liver metastases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Frequency of hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sarcopenia Prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skeletal Muscle Index Changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of clinical patient demographic data collected
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Amount of clinical patient medical treatment and outcome data collected
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of biospecimens collected for a tissue repository
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: quantity of circulating cell-free mitochondrial DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in plasma GIP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in plasma GLP-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Meaningful Change in Symptom Categories
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Response to adoptive transfer of autologous CMV-specific CD8+ T-cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: substance outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: behavior problems
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in exclusive toilet usage rate
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Incidence of Treatment Related adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Identification of Maximum Tolerated Dose (MTD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of Participants With Confirmed Overall Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: well-being of patients
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: 30 days survival
Endpoint domain: Mortality/survival
Primary endpoint: Wrist pain and disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Recurrent upper gastrointestinal bleeding within 30 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Cellulite severity change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global Aesthetic Improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Hip and Thigh Circumference Measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ultraviolet B (UVB) Heat Pain Detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cold Pressor Time to Intolerable Pain Threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Electrical Pain Tolerance Threshold (Single Stimulus)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Swanson, Nolan and Pelham, Version Ⅳ Rating Scale (SNAP-Ⅳ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Global Impressions-Improvement scale (CGI-I)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: side effect assessment
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of stroke-associated pneumonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Get Ready To Read- Revised score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Mean change in frequency of moderate to severe vasomotor symptoms (VMS) from baseline to Week 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in frequency of moderate to severe VMS from baseline to Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in severity of moderate to severe vasomotor symptoms (VMS) from baseline to Week 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in severity of moderate to severe VMS from baseline to Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Response Rate in MDS Cohort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Response Rate in AML Cohort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in mean of kinematic data for walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in mean of movement range for affected joints
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Difference in mean of energy expenditure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With Post-operative Ultrasound Without Evidence of Thromboembolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Indices of glutamate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pulmonary cardiac output (Qp)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Event free-survival
Endpoint domain: Mortality/survival
Primary endpoint: Prognosis and diagnosis values of qPCR testing in glioma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: inflammatory changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety of single low-dose primaquine
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Dose-limiting Toxicity (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Adverse Events of Grade 3 or Higher Severity
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of new drug use disorder treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Blood Eosinophil count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Duration of complete remission
Endpoint domain: Mortality/survival
Primary endpoint: Safety at 30 Days
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of Patients With Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response Rate at Time of Surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration and degree of pain relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Left CA1 Cerebral Blood Volume (CBV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: changes in daily dietary protein intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cytopenias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Headache Impact Test (HIT-6)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Score obtained in decision-making tasks
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Percentage of Participants With Complete Response at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Neuropsychiatric Inventory (NPI) Total
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinician's Interview-Based Impression of Change Plus Caregiver Input (CIBIC-plus) Total
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change From Baseline in J-ZBI (Japanese- Zarit Caregiver Burden Interview) Total
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: Change From Baseline in Mini-mental State Examination (MMSE) Total
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aging Males Symptoms questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in stroke volume index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Intervention acceptability for patients
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status